News
MYGN
5.45
+2.93%
0.16
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches
NASDAQ · 1d ago
Weekly Report: what happened at MYGN last week (0630-0704)?
Weekly Report · 1d ago
Weekly Report: what happened at MYGN last week (0623-0627)?
Weekly Report · 06/30 09:10
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Simply Wall St · 06/25 10:18
Weekly Report: what happened at MYGN last week (0616-0620)?
Weekly Report · 06/23 09:09
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
NASDAQ · 06/16 12:25
Weekly Report: what happened at MYGN last week (0609-0613)?
Weekly Report · 06/16 09:10
Weekly Report: what happened at MYGN last week (0602-0606)?
Weekly Report · 06/09 09:10
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?
NASDAQ · 06/06 13:09
Balancing Optimism and Caution: Hold Rating for Myriad Genetics Amid Strategic Shifts and Uncertainties
TipRanks · 06/05 04:27
Myriad Genetics Shares Higher on Prenatal Screen Update
Dow Jones · 06/03 19:16
Myriad Genetics announces early access to FirstGene Multiple Prenatal Screen
TipRanks · 06/03 13:05
Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study
NASDAQ · 06/02 17:20
Myriad Genetics shares MRD data from MONSTAR-SCREEN 3 study
TipRanks · 06/02 13:15
Myriad Genetics Announces MONSTAR-SCREEN 3 Data, Advancing Pan-Cancer MRD Testing
Benzinga · 06/02 13:05
Weekly Report: what happened at MYGN last week (0526-0530)?
Weekly Report · 06/02 09:11
Weekly Report: what happened at MYGN last week (0519-0523)?
Weekly Report · 05/26 09:11
Target slides after cutting sales forecast: Morning Buzz
TipRanks · 05/21 16:10
UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
TipRanks · 05/21 13:35
Myriad Genetics Price Target Cut to $6.00/Share From $20.00 by Scotiabank
Dow Jones · 05/21 13:33
More
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.